PDF(Pubmed)
Abstract：
UNASSIGNED: Patients with Cushing\'s disease (CD) often experience slow recovery of bone mineral density (BMD), and the effectiveness of anti-osteoporosis drugs in young CD patients who have achieved biochemical remission after surgery is not well understood. Therefore, we aimed to explore whether bisphosphonates could help accelerate the recovery of osteoporosis in young CD patients with remission.
UNASSIGNED: We retrospectively enrolled 34 young patients with CD who achieved postoperative biochemical remission. All patients suffered from osteoporosis before surgery and were divided into postoperative bisphosphonate treatment group (16 cases) and without bisphosphonate treatment group (18 cases). Clinical data, BMD (Z Value), and bone turnover markers were collected at the time of diagnosis and one year after successful tumor resection.
UNASSIGNED: The Z values in the lumbar spine showed slight improvement in both groups at follow-up compared to baseline, but this improvement was not statistically significant. There was no significant difference observed between the two groups at follow-up. One year after operation, bone formation markers (OC and P1NP) were significantly higher than those at baseline in both groups. However, OC and P1NP in the bisphosphonate treatment group were lower than those in control group at one year follow-up. In without bisphosphonate treatment group, β-CTX from follow-up visit was higher than that at baseline, while no significant difference was observed in the bisphosphonate treatment group before and after surgery.
UNASSIGNED: Young patients with Cushing\'s disease combined with osteoporosis might not benefit from bisphosphonate therapy for osteoporosis recovery in the first year after achieving biochemical remission.
UNASSIGNED: We retrospectively enrolled 34 young patients with CD who achieved postoperative biochemical remission. All patients suffered from osteoporosis before surgery and were divided into postoperative bisphosphonate treatment group (16 cases) and without bisphosphonate treatment group (18 cases). Clinical data, BMD (Z Value), and bone turnover markers were collected at the time of diagnosis and one year after successful tumor resection.
UNASSIGNED: The Z values in the lumbar spine showed slight improvement in both groups at follow-up compared to baseline, but this improvement was not statistically significant. There was no significant difference observed between the two groups at follow-up. One year after operation, bone formation markers (OC and P1NP) were significantly higher than those at baseline in both groups. However, OC and P1NP in the bisphosphonate treatment group were lower than those in control group at one year follow-up. In without bisphosphonate treatment group, β-CTX from follow-up visit was higher than that at baseline, while no significant difference was observed in the bisphosphonate treatment group before and after surgery.
UNASSIGNED: Young patients with Cushing\'s disease combined with osteoporosis might not benefit from bisphosphonate therapy for osteoporosis recovery in the first year after achieving biochemical remission.
摘要：
■库欣病（CD）患者的骨密度（BMD）通常恢复缓慢，对于手术后生化缓解的年轻CD患者，抗骨质疏松药物的有效性尚不清楚。因此,我们的目的是探讨双膦酸盐能否帮助缓解的年轻CD患者加速骨质疏松的恢复.
■我们回顾性纳入了34例术后生化缓解的年轻CD患者。所有患者术前均出现骨质疏松,分为术后双膦酸盐治疗组(16例)和无双膦酸盐治疗组(18例)。临床数据,BMD(Z值),在诊断时和成功切除肿瘤后一年收集骨转换标志物。
■随访时，两组腰椎的Z值与基线相比均有轻微改善，但这种改善没有统计学意义.随访时两组间无显著差异。手术一年后,两组骨形成标志物(OC和P1NP)均显著高于基线.然而,随访1年,双膦酸盐治疗组OC和P1NP均低于对照组。在没有双膦酸盐治疗组中，随访时的β-CTX高于基线，而双膦酸盐治疗组手术前后无显著差异。
■患有库欣病合并骨质疏松症的年轻患者在获得生化缓解后的第一年可能无法从二膦酸盐治疗中受益，以恢复骨质疏松症。
■我们回顾性纳入了34例术后生化缓解的年轻CD患者。所有患者术前均出现骨质疏松,分为术后双膦酸盐治疗组(16例)和无双膦酸盐治疗组(18例)。临床数据,BMD(Z值),在诊断时和成功切除肿瘤后一年收集骨转换标志物。
■随访时，两组腰椎的Z值与基线相比均有轻微改善，但这种改善没有统计学意义.随访时两组间无显著差异。手术一年后,两组骨形成标志物(OC和P1NP)均显著高于基线.然而,随访1年,双膦酸盐治疗组OC和P1NP均低于对照组。在没有双膦酸盐治疗组中，随访时的β-CTX高于基线，而双膦酸盐治疗组手术前后无显著差异。
■患有库欣病合并骨质疏松症的年轻患者在获得生化缓解后的第一年可能无法从二膦酸盐治疗中受益，以恢复骨质疏松症。
